Skip to content
OpenCapital
Get started

Rapport Therapeutics, Inc. RAPP Proceeds from disposition of marketable securities and other investments

Proceeds from disposition of marketable securities and other investments at other companies

MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc. MPLT
——

Other financials

Income statement

See full
Revenue$20.0M—
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.91B+309%

Returns & leverage

See full
Return on equity-28.3%—
Debt / equity0×0.0×
Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments?
Rapport Therapeutics, Inc. (RAPP) reported proceeds from disposition of marketable securities and other investments of $58.32M in Q1 2026.
How has Rapport Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments changed year-over-year?
Rapport Therapeutics, Inc.'s proceeds from disposition of marketable securities and other investments decreased by 9.7% year-over-year, from $64.56M to $58.32M.